Ex­er­cise in a pill? That's the fo­cus of Cam­bri­an's new pipeline com­pa­ny

In line with its an­ti-ag­ing cen­tral theme, Cam­bri­an Bio­Phar­ma has a new clin­i­cal can­di­date to work with, go­ing af­ter what CEO James Pey­er de­scribed as a “Holy Grail tar­get.”

The New York drug de­vel­op­er an­nounced the launch of its newest pipeline com­pa­ny, Am­pli­fi­er Ther­a­peu­tics, Tues­day morn­ing. Cam­bri­an is in­vest­ing $26 mil­lion in­to Am­pli­fi­er to kick things off, Pey­er told End­points News. James Hall, the ex-head of car­dio­vas­cu­lar BD at As­traZeneca, is at the helm as Am­pli­fi­er’s CEO.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER